Tag Archives: TCR

November, 2018

20 November
Genentech to Pay $100 Million to Immunocore to Co-Develop Investigational Drug Targeting Tumors Expressing MAGE-A4

(Oxford, UK and Conshohocken, US, 19 November 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today announces it has entered into a new partnership with Genentech, a member of …
Share

19 July
Kite and Gadeta Collaborate to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors

SANTA MONICA, Calif. & UTRECHT, Netherlands–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in …
Share

14 May
Medigene Expands T-Cell Receptor Deal with Bluebird bio to up to $1.5 Billion

Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, today announced the significant expansion of its successful strategic alliance with bluebird bio, a leader in gene and cell therapies, focusing on the research and development of T cell receptor-modified T cell (TCR-T) immunotherapies for the treatment of cancer. “We are delighted to …
Share

26 July
Adaptive’s ImmunoSEQ Platform to be Used for Immunosequencing-Based Biomarker Discovery in NCI Trials

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, a pioneer in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors (TCRs and BCRs) of the adaptive immune system, today announced a translational collaboration with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), part of the National Institutes of …
Share

24 August
Cell Medica and UCL Partner to Develop Modified T Cell Receptor Cancer Drugs

LONDON–(BUSINESS WIRE)–Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, has signed a research collaboration with UCL (University College London) aiming to utilize UCL’s novel T cell receptor (TCR) technology to generate leading-edge modified TCR products for the treatment of cancer. The collaboration also …
Share

22 April
Juno’s Investigational CAR T Cell Product Candidates Show Promise in Patients with B-Cell and Mesothelioma Cancers

SEATTLE–(BUSINESS WIRE)–Apr. 20, 2016– Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, early clinical data from two oral presentations for two product candidates at the American Association for Cancer Research …
Share

13 January
Juno Therapeutics Acquires AbVitro, Adding Next-Generation Single Cell Sequencing Capabilities

SEATTLE–(BUSINESS WIRE)–Jan. 11, 2016– Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it has acquired AbVitro, Inc., a privately held biotechnology company based in Boston, Massachusetts. The acquisition provides Juno with a leading next-generation …
Share